Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $211K rose 56.3% year over year, behind the +132.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 39.7% from the prior quarter. Over 3 fiscal years it compounded at +52.6% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +56.3% toward the trailing-twelve-month pace of +132.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$211K+39.7% QoQ
Last fiscal yearDec 2025
$572K+33.6% YoY
LTMMar 2026
$648K+132.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.3%——
1 year+33.6%——
3-year CAGR+52.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
572K USD
Year-over-year change
+33.6%
4-year CAGR
+157.6%

Depreciation & Amortization vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +132.3% is the highest of 9, against a peer median of -15.7%.
  • Over three fiscal years its annual growth of +52.6% compares with a peer median of +26.8%.
UNCY Competitors
Depreciation & Amortization for UNCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$7.74M USD-13.3%+13.9%3.0%
CBUSCibus, Inc.LTM Mar 2026$5.46M USD-18.2%+56.9%127.4%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.28M CAD-57.9%+10.7%12.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$1.74M USD+3.4%—44.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.21M USD+8.3%+36.2%—
BMEABiomea Fusion, Inc.LTM Mar 2026$960K USD-46.5%+26.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K USD+132.3%+52.6%—
IMUXImmunic, Inc.LTM Mar 2026$158K USD+4.6%+29.7%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$131K USD-84.0%-41.1%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding UNCY) —-15.7%+26.8%28.3%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Depreciation & Amortization13K161K284K428K572K
Deferred Income Tax00000
Stock-Based Compensation966K1.05M1.77M2.35M2.64M
Change in Working Capital(105K)1.18M(93K)(427K)(5.95M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.24M1.27M1.28M790K(2.51M)
Other Working Capital(1.35M)(89K)(1.37M)(1.22M)(3.45M)
Other Non-Cash Items3.38M21K10.3M5.8M(2.02M)
Operating Cash Flow(5.77M)(15.65M)(18.28M)(28.58M)(31.32M)
Capital Expenditures(29K)(2K)(12K)(72K)(24K)
Acquisitions (Net)00000
Purchases of Investments0000(12.07M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(29K)(2K)(12K)(72K)(12.1M)
Debt Repayment(15K)0000
Common Stock Issued22.27M11K0683K48.08M
Common Stock Repurchased00000
Dividends Paid000(1.1M)0
Other Financing Activities119K(482K)(2.65M)(4.5M)(1.61M)
Financing Cash Flow22.38M(471K)27.54M45.09M46.47M
Effect of Forex Changes00000
Net Change in Cash16.58M(16.12M)9.25M16.44M3.06M
Free Cash Flow(5.8M)(15.65M)(18.3M)(28.65M)(31.34M)

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.